The DIM One Health 2.0 project led by Inserm and Prof. Jean-Daniel Lelièvre, accredited by the Ile-de-France region

The COVID-19 pandemic is a reminder of the reality of so-called emerging infectious diseases. These diseases represent in a caricatural way the “One Health” concept of a single health shared by humans and animals in their environment. This concept, which has become obvious in recent years, is the subject of numerous national and international projects.

The DIM One Health 2.0 project led by INSERM by Prof. Jean-Daniel Lelièvre, Lévy team, is a continuation of the DIM One Health and aims to fund innovative projects by teams whose purpose is to identify the events that can lead to the emergence or dissemination of an infectious agent in different ecosystems. It will be involved in assessing infectious risks while proposing operational solutions applicable to the Ile-de-France region that respond to both human and animal health and environmental issues.

It relies on almost all partners working in the field of infectious diseases in the region with disciplinary fields covering aspects of biological, environmental, mathematical, medical, social and public health sciences. This project brings together 4 universities (University of Paris (UP), Sorbonne University (SU), University of Paris Est Créteil (UPEC), University of Paris Saclay),

9 Laboratories of Excellence and 10 major research organizations: Anses, CEA, EnvA, IRD (Institute of Research for Development), IRBA (Institute of Biomedical Research of the Armed Forces) , INRAE, Pasteur Institute, INSERM, Micalis Institute, Microb’Up Institute of UP, MNHN, the national agency Santé Publique France, the Healthi action of the Faculty of Pharmacy of the University of Paris Saclay, the interdisciplinary project “Health and therapeutic innovation”, as well as the labEx IBEID (Integrative Biology of Emerging Infectious Diseases) of the Institut Pasteur, VRI (Vaccine research Institute), Futurs Urbains (health in the city) and, ParaFrap (French Alliance against parasitic diseases).

The DIM also brings together infectiology and biomanufacturing companies: DaVolterra, DrugAbilis, Eligo, GMT Science, LinKinVax, Seppic SA, and players in the field of technology transfer: the Medicen Paris Region competitiveness cluster, the Carnot Institute France Futur Elevage, INSERM Transfert and the SATT Erganeo

The final objectives of this One Health 2.0 DIM are, on the one hand, to obtain funding for projects on this theme and, on the other hand, to structure the network of interactions between academic and private structures already existing in the region. Obtaining this DIM reinforces the strong One Health axis between the Faculty of Health and the EnvA for our site.

UPEC news of February 22, 2022